Portal de Periódicos da CAPES

Defective hydroxylation of bufuralol associated with side‐effects of the drug in poor metabolisers [letter]

1982; Wiley; Volume: 13; Issue: 5 Linguagem: Inglês

10.1111/j.1365-2125.1982.tb01453.x

1365-2125

Pierre Dayer, A. Kubli, A Küpfer, François Courvoisier, L Balant, J Fabré,

Pharmaceutical studies and practices

British Journal of Clinical PharmacologyVolume 13, Issue 5 p. 750-752 Free Access Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers [letter] P Dayer, P DayerSearch for more papers by this authorA Kubli, A KubliSearch for more papers by this authorA Kupfer, A KupferSearch for more papers by this authorF Courvoisier, F CourvoisierSearch for more papers by this authorL Balant, L BalantSearch for more papers by this authorJ Fabre, J FabreSearch for more papers by this author P Dayer, P DayerSearch for more papers by this authorA Kubli, A KubliSearch for more papers by this authorA Kupfer, A KupferSearch for more papers by this authorF Courvoisier, F CourvoisierSearch for more papers by this authorL Balant, L BalantSearch for more papers by this authorJ Fabre, J FabreSearch for more papers by this author First published: May 1982 https://doi.org/10.1111/j.1365-2125.1982.tb01453.xCitations: 32AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat References BALANT, L., GORGIA, A., TSCHOPP, J. M., REVILLARD, C. & RE, FAB J. (1976). Pharmacocinétique de deux médicaments β-bloquants: détection d'une anomalie pharmacogénetique Schweiz. med. Wschr., 106, 1403– 1407. BALANT, L., FRANCIS, R.J., TSCHOPP, J. M., TINGUELY, D., ESTREICHER, J. & FABRE, J. (1978a): Pharmacocinétique du bufuralol chez l'homme. Pharm. Acta Helv., 53, 307– 313. BALANT, L., DAYER, P. & FABRE, J. (1978b). Poly-morphism in drug metabolism. Br. med. J., 2, 1299. BALANT, L., FRANCIS, R.J., TOZER, T.N., MARMY, A., TSCHOPP, J. M. & FABRE J. (1980). Influence of renal failure on the hepatic clearance of bufuralol in man. J. Pharmacokinet. Biopharm., 8, 421– 438. BERTILSSON, L., DENGLER, H.J., EICHELBAUM, M. & SCHULZ H. U. (1980). Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine. Eur. J. clin. Pharmac., 17, 153– 155. DA VIES, D.S., KAHN, G.C., MURRAY, S., BRODIE, M.J. & BOOBIS, A.R. (1981). Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver. Br. J. clin. Pharmac., 11, 89– 91. EICHELBAUM, M., SPANNBRUCKER, N., STEINCKE, B. & DENGLER, H.J. (1979). Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur. J. clin. Pharmac., 16, 183– 187. FRANCIS, R.J., EAST, P.B., McLAREN, S.J. & LARMAN, J. (1976). Determination of bufuralol and its metabolites in plasma by mass fragmentography and by gas chromatography with electron capture detection. Biomed. Mass. Spectrom., 3, 281– 285. HAEFELFINGER, P. (1980). Determination of bufuralol and its major metabolites in plasma by high-performance liquid chromatography. J. Chromatogr., 221, 327– 335. KILBORN, J.R. & TURNER P. (1974). Ro 3–4787, a new β-adrenoceptor blocking agent: studies in normal volunteers. Br. J. clin. Pharmac., 1, 143– 149. MAHGOUB, A., IDLE, J.R., DRING, L.G., LANCASTER, R. & SMITH, R.L. (1977). Polymorphic hydroxylation of debrisoquine in man. Lancet, ii, 584– 586. EVANS, PRICE D.A., MAHGOUB, A., SLOAN, T.P., IDLE, J.R. & SMITH, R.L. (1980). A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J. med. Genet., 17, 102– 105. SLOAN, T.P., MAHGOUB, A., LANCASTER, R., IDLE, J.R. & SMITH, R.L. (1978). Polymorphism of carbon oxidation of drugs and clinical implications. Br. med. J., 2, 655– 657. SLOAN, T.P., IDLE, J.R. & SMITH, R.L. (1981). Influence of DH/DLsalleles regulating debrisoquine oxidation on phenytoin hydroxylation. Clin. Pharmac. Ther., 29, 493– 497. TSCHOPP, J.M., GORGIA, A., BALANT, L., REVILLARD, C., FRANCIS, R.J. & FABRE, J. (1978). Rôle des métabolites dans les relations entre la pharmacocinetique et l'effet des agents β-bloquants. Expériences avec le tolamolol et le bufuralol. Schweiz. med. Wschr., 108, 756– 764. Citing Literature Volume13, Issue5May 1982Pages 750-752 ReferencesRelatedInformation